Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study


Disclosures: Conflict-of-interest disclosure: D.R. has consulting or advisory roles for Celgene, Pfizer, MSD, Astellas Pharma, Novartis, and Boehringer, receives research funding from Celgene and receives travel, accommodations or expenses from JAZZ pharmaceutical, NOVO Nordisk and Girfols. C.M.Z. has consulting or advisory roles for Pfizer, Daiichi Sankyo, Celgene, Novartis, Bristol-Myers Squibb, and Gilead Sciences and receives research funding from Karyopharm Therapeutics, Pfizer, Bristol-Myers Squibb, and GlaxoSmithKline. C.R. has consulting or advisory roles for Pfizer, Amgen, and Genentech. B.B. receives travel, accommodations or expenses from Amgen. T.K. has consulting or advisory roles for Loxo and Pfizer. The remaining authors declare no competing financial interests.